All In Biotech

Drug Trial Radar · NCT05226598

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 739 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

739

Actual

Start

Mar 24, 2022

Primary completion

Sep 24, 2024

Study completion Jan 9, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%.

Conditions

  • Metastatic Non-Small Cell Lung Cancer

Interventions

  • Pembrolizumab/VibostolimabBiological

    Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations

  • CarboplatinDrug

    Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations

  • CisplatinDrug

    Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations

  • PaclitaxelDrug

    Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations

  • Nab-paclitaxelDrug

    Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations

  • PemetrexedDrug

    Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision

  • PembrolizumabBiological

    Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%Time frame: Up to approximately 29 months

Locations

149 sites in 19 countries. Site status is shown where the registry gives one.

  • UCHealth Memorial Hospital-Heme Onc ( Site 0003)

    Colorado Springs, Colorado

  • University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0031)

    Fort Collins, Colorado

  • Mayo Clinic in Florida ( Site 0022)

    Jacksonville, Florida

  • Mount Sinai Hospital ( Site 0011)

    Chicago, Illinois

  • University of Chicago Medical Center ( Site 0015)

    Chicago, Illinois

  • New England Cancer Specialists ( Site 0008)

    Scarborough, Maine

  • Cancer and Hematology Centers of Western Michigan ( Site 0002)

    Grand Rapids, Michigan

  • Mayo Clinic in Rochester, Minnesota ( Site 0030)

    Rochester, Minnesota

  • Stony Brook University-Cancer Center ( Site 0013)

    Stony Brook, New York

  • Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0012)

    Lancaster, Pennsylvania

  • Charleston Oncology ( Site 0019)

    Charleston, South Carolina

  • University of Virginia Cancer Center ( Site 0018)

    Charlottesville, Virginia

  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0206)

    La Rioja, Argentina

  • Centro de Oncología e Investigación de Buenos Aires ( Site 0203)

    Berazategui, Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0204)

    Mar del Plata, Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0209)

    ABB, Buenos Aires F.D., Argentina

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0202)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Sanatorio Parque ( Site 0205)

    Rosario, Santa Fe Province, Argentina

  • Hospital Provincial del Centenario ( Site 0212)

    Rosario, Santa Fe Province, Argentina

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0701)

    Vienna, Austria

  • Klinik Penzing-2. Lungenabteilung ( Site 0702)

    Vienna, State of Vienna, Austria

  • Medizinische Universität Graz ( Site 0704)

    Graz, Styria, Austria

  • Medizinische Universitaet Innsbruck ( Site 0703)

    Innsbruck, Tyrol, Austria

  • Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0705)

    Linz, Upper Austria, Austria

  • Kepler Universitätsklinikum ( Site 0707)

    Linz, Upper Austria, Austria

  • Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 0406)

    Rio de Janeiro, Brazil

  • Hospital Paulistano ( Site 0401)

    São Paulo, Brazil

  • Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0403)

    Natal, Rio Grande do Norte, Brazil

  • Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0405)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clínica de Oncologia Reichow ( Site 0407)

    Blumenau, Santa Catarina, Brazil

  • Centro de Investigación Oncológica del Norte ( Site 0504)

    Antofagasta, Chile

  • James Lind Centro de Investigación del Cáncer ( Site 0502)

    Temuco, Araucania, Chile

  • CIDO SpA-Oncology ( Site 0508)

    Temuco, Araucania, Chile

  • Biocenter ( Site 0514)

    Concepción, Biobio, Chile

  • FALP-UIDO ( Site 0505)

    Santiago, Region M. de Santiago, Chile

  • Centro de Oncología de Precisión ( Site 0515)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0510)

    Santiago, Region M. de Santiago, Chile

  • ONCOCENTRO APYS-ACEREY ( Site 0503)

    Viña del Mar, Valparaiso, Chile

  • Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2619)

    Hefei, Anhui, China

  • Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2602)

    Beijing, Beijing Municipality, China

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.